
PDS Biotechnology Corp
100
Recent developments highlight PDS Biotechnology's strategic refocus on PDS0301, capital raising efforts, ongoing clinical trial progress, and regulatory interactions.
- PDS Biotechnology announced a strategic refocus in August 2026 to prioritize PDS0301 as its lead development program, ceasing further internal investments in PDS0101 and discontinuing the VERSATILE-003 Phase 3 trial [S2].
- The company intends to pursue strategic partnerships or externally funded opportunities for continued development of PDS0101 [S2].
- PDS Biotechnology raised up to $22.55 million in a PIPE financing led by Dr. Patrick Soon-Shiong in September 2026 [N3].
- The company reported a net loss of approximately $7.6 million and basic and diluted EPS of -$0.11 for the quarter ended September 30, 2026, with cash and equivalents of $15.2 million [S2].
- PDS Biotechnology faces Nasdaq listing risks due to its common stock price being below $1.00 for over 30 consecutive trading days as of July 2026, with a 180-day grace period to regain compliance [S2].
- Recent news coverage notes PDS Biotechnology among leading biotech stock movers and highlights its clinical and financing activities [N1][N2].
PDS Biotechnology Corp is a clinical-stage biopharmaceutical company developing immunotherapy products based on its proprietary Versamune® platform. The company’s lead candidate, PDS0301, is an IL-12 tumor-targeted immunocytokine in clinical development for metastatic colorectal cancer and other solid tumors. The company has ceased internal development of PDS0101 and discontinued its VERSATILE-003 Phase 3 trial, focusing resources on PDS0301 and seeking external partnerships for PDS0101. PDS Biotechnology has not yet generated product revenue and continues to incur operating losses. As of September 30, 2026, it held $15.2 million in cash and equivalents and reported a net loss of $7.6 million for the quarter. The company faces Nasdaq listing risks due to its stock price being below the minimum required threshold. Leadership includes experienced biotech executives and a board with expertise in biopharmaceuticals and oncology.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. PDS Biotechnology Corp is a clinical-stage biopharmaceutical company focused on immunotherapy product candidates, with no approved products or revenue to date. The company has strategically refocused its pipeline to prioritize PDS0301, a tumor-targeted IL-12 immunocytokine in clinical development for metastatic colorectal cancer, while discontinuing internal development of PDS0101 and its Phase 3 trial. As of September 30, 2026, the company held $15.2 million in cash and equivalents, reported a net loss of $7.6 million for the quarter, and maintains a strong liquidity position with a current ratio of 3.62. Risks include dependence on clinical success of PDS0301, challenges in securing partnerships for PDS0101, Nasdaq listing compliance risks, and ongoing need for capital to fund operations.
The company’s strategic refocus on PDS0301 concentrates resources on a promising immunocytokine candidate with Phase 2 clinical data in metastatic colorectal cancer. Successful advancement through planned Phase 2b trials and regulatory alignment on endpoints could enhance clinical and commercial prospects. The recent $22.55 million PIPE financing led by a notable investor provides capital to support development. The Versamune® platform’s potential to generate differentiated immunotherapies could enable future product expansion and partnerships.
PDS Biotechnology faces significant risks including the possibility that PDS0301 clinical trials may not replicate early positive results, and that the narrowed pipeline increases dependence on a single candidate. The discontinuation of PDS0101 internal development and Phase 3 trial may reduce pipeline breadth and value if partnerships are not secured. The company’s stock price is below Nasdaq’s minimum bid price requirement, risking delisting. Continued operating losses and limited cash resources create ongoing financing risks that could impact development and operations.
PDS Biotechnology’s moat is based on its proprietary Versamune® platform technology for immunotherapy and its clinical-stage product candidates targeting oncology indications. The company’s focus on tumor-targeted IL-12 immunocytokines and HPV-related immunotherapies represents a specialized niche in cancer immunotherapy. However, as a clinical-stage company without approved products or revenue, its competitive position depends heavily on successful clinical development, regulatory approvals, and strategic partnerships. Intellectual property protections and clinical data will be critical to establishing a sustainable competitive advantage.
• Nasdaq Listing Compliance Risk: The company’s common stock price has been below the $1.00 minimum bid price required by Nasdaq for over 30 consecutive trading days as of July 2026, with a 180-day grace period to regain compliance. Failure to comply may result in delisting, adversely affecting liquidity, investor confidence, and capital raising ability [S2].
• Clinical Development Risk: PDS0301 is in mid-stage clinical development with Phase 2 data supporting its potential. Future trials, including planned Phase 2b studies, may not confirm efficacy or safety, which could materially impact the company’s prospects [S2].
• Strategic Refocus and Pipeline Concentration Risk: The company’s strategic decision to prioritize PDS0301 and discontinue internal development of PDS0101 narrows its clinical pipeline, increasing dependence on PDS0301’s success. Failure to secure partnerships for PDS0101 may diminish its value [S2].
• Financial and Going Concern Risk: PDS Biotechnology has incurred significant losses and has limited cash resources ($15.2 million as of September 30, 2026). The ability to continue operations depends on raising additional capital or securing partnerships. Failure to do so may require delaying or terminating development programs or ceasing operations [S2].
• Regulatory and Commercialization Risk: The company has no approved products and must obtain regulatory approvals before marketing. Even if approved, successful commercialization depends on pricing, reimbursement, manufacturing, market acceptance, and competitive dynamics [S2].
Business trends: Strategic refocus on PDS0301 with discontinuation of PDS0101 internal development narrows pipeline focus; ongoing clinical development and capital raising efforts.
Execution milestones: Advancement of PDS0301 through planned Phase 2b trials; securing strategic partnerships for PDS0101; maintaining Nasdaq listing compliance.
Key risks: Clinical trial outcomes for PDS0301; ability to secure partnerships for PDS0101; Nasdaq listing compliance and capital raising challenges impacting operational continuity.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- PDS Biotechnology Corp is a clinical-stage biopharmaceutical company focused on developing immunotherapy product candidates based on its Versamune® platform and related technologies [S1].
- The company has no products approved for sale and has never generated product revenue [S2].
- PDS Biotechnology's lead development program is PDS0301, a tumor-targeted IL-12 immunocytokine in clinical development for metastatic colorectal cancer and other solid tumors [S2].
- The company has strategically refocused to prioritize PDS0301 and has ceased further internal investments in PDS0101, discontinuing the VERSATILE-003 Phase 3 clinical trial for PDS0101 in HPV16-positive head and neck squamous cell carcinoma [S2].
- PDS Biotechnology intends to pursue strategic partnerships or externally funded opportunities for continued development of PDS0101 [S2].
- The company has reported Phase 2 clinical data supporting PDS0301 but acknowledges risks that future trials may not replicate these results [S2].
- As of September 30, 2026, PDS Biotechnology had $15.2 million in cash and cash equivalents, current assets of approximately $18.4 million, current liabilities of about $5.1 million, a current ratio of 3.62, and a cash ratio of 3.0 [S2].
- The company reported a net loss of approximately $7.6 million and basic and diluted EPS of -$0.11 for the quarter ended September 30, 2026 [S2].
- PDS Biotechnology has incurred significant losses since inception with an accumulated deficit of $241.3 million as of September 30, 2026 [S2].
- The company faces Nasdaq listing risks due to its common stock price being below $1.00 for over 30 consecutive trading days as of July 2026, with a 180-day grace period to regain compliance [S2].
- The company’s leadership includes CEO Frank Bedu-Addo, Ph.D., with extensive biotech executive experience, and a board with diverse expertise in biopharmaceuticals, legal, and oncology fields [S1].
- Recent news highlights include a $22.55 million PIPE financing led by Dr. Patrick Soon-Shiong, ongoing clinical trial developments, and strategic business updates [N3][N1][N2].
Generated 2026-11-16
- S1 | 2026-04-28 | 10-K/A
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-09-15 | www.nasdaq.com | Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers | https://www.nasdaq.com/articles/biotech-stocks-gain-ground-pds-biotech-clene-indaptus-lead-movers
- N2 | 2026-09-08 | www.nasdaq.com | 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara | https://www.nasdaq.com/articles/5-biotech-stocks-watch-bluejay-pharvaris-roivant-pdsb-atara
- N3 | 2026-09-08 | www.nasdaq.com | PDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong | https://www.nasdaq.com/articles/pds-biotech-raises-2255m-pipe-led-dr-patrick-soon-shiong
- N4 | 2026-05-27 | www.nasdaq.com | PDSB Q4 2025 Earnings Call Transcript | https://www.nasdaq.com/articles/pdsb-q4-2025-earnings-call-transcript
- N5 | 2026-05-13 | www.nasdaq.com | PDSB Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/pdsb-q1-2026-earnings-transcript
- N6 | 2026-05-13 | www.nasdaq.com | PDS Biotechnology Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/pds-biotechnology-q1-earnings-call-highlights
- N7 | 2026-04-17 | www.nasdaq.com | Weekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials | https://www.nasdaq.com/articles/weekly-buzz-fda-okays-tvtx-phg-rejects-repl-aip-snaps-avns-pds-hoth-syre-paces-trials
- N8 | 2026-03-27 | www.nasdaq.com | Pre-Market Earnings Report for March 30, 2026 : SGML, BCAX, NMRA, CBAT, PDSB, PAVM | https://www.nasdaq.com/articles/pre-market-earnings-report-march-30-2026-sgml-bcax-nmra-cbat-pdsb-pavm
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


